Persistent or dysregulated STAT3 activation has been shown to drive tumor cell proliferation, apoptosis evasion, and immune modulation, thereby promoting resistance to CDK4/6 inhibitors (Dong et al., 2024; Wu et al., 2024). Here, CDK4 is linked to neoplasm.